Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with β-thalassemia

Antonio Piga, Silverio Perrotta, Maria Rita Gamberini, Ersi Voskaridou, Angela Melpignano, Aldo Filosa, Vincenzo Caruso, Antonello Pietrangelo, Filomena Longo, Immacolata Tartaglione, Caterina Borgna-Pignatti, Xiaosha Zhang, Abderrahmane Laadem, Matthew L. Sherman, Kenneth M. Attie

Blood (2019) 133 (12): 1279–1289.

https://doi.org/10.1182/blood-2018-10-879247

Published: 2019

Includes: Supplemental data

Journal Articles

Luspatercept Increases Hemoglobin, Decreases Transfusion Burden and Improves Iron Overload in Adults with Beta-Thalassemia

Antonio G. Piga, MD, Immacolata Tartaglione, MD, Rita Gamberini, MD, Ersi Voskaridou, MD, Angela Melpignano, MD, Paolo Ricchi, MD, Vincenzo Caruso, MD, Antonello Pietrangelo, MD, Xiaosha Zhang, Dawn M. Wilson, Ashley Leneus, Abderrahmane Laadem, MD, Matthew L. Sherman, MD, Kenneth M. Attie, MD

Blood (2016) 128 (22): 851.

https://doi.org/10.1182/blood.V128.22.851.851

Published: 2016

Journal Articles

Luspatercept (ACE-536) Reduces Disease Burden, Including Anemia, Iron Overload, and Leg Ulcers, in Adults with Beta-Thalassemia: Results from a Phase 2 Study

Antonio Piga, MD, Silverio Perrotta, MD, M.Rita Gamberini, MD, Ersi Voskaridou, MD, Angela Melpignano, Aldo Filosa, MD, Antonello Pietrangelo, MD, Vincenzo Caruso, MD, Gian Luca Forni, MD, Xiaosha Zhang, Ashley Bellevue, Dawn Wilson, Abderrahmane Laadem, MD, Matthew L. Sherman, MD, Kenneth M. Attie, MD

Blood (2015) 126 (23): 752.

https://doi.org/10.1182/blood.V126.23.752.752

Published: 2015

Journal Articles

Randomized, Open Label, Phase IIa Controlled Trials Evaluating the Safety of the Association of Deferasirox with Standard Antiviral Therapy (Peg-interferon and Ribavirin) in Patients with Chronic Hepatitis C

Francesca Pileri, MD, Alberto Vegetti, MD, Luca De Pietri, MD, Gianluca Abbati, MD, Paolo Ventura, MD, Maria Rita Gamberini, MD, Vincenzo Caruso, Francesca Ferrara, Antonello Pietrangelo, MD, PhD

Blood (2014) 124 (21): 4075.

https://doi.org/10.1182/blood.V124.21.4075.4075

Published: 2014

Journal Articles

Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel

Blood (2010) 116 (16): 2875–2883.

https://doi.org/10.1182/blood-2009-11-248724

Published: 2010

Journal Articles

A Phase I/II, Open-Label, Dose-Escalation Trial of Once-Daily Oral Chelator Deferasirox to Treat Iron Overload in HFE-Related Hereditary Hemochromatosis: Final Results of the Core Study.

Pradyumna D. Phatak, Pierre Brissot, Herbert Bonkovsky, Mark Wurster, Lawrie Powell, Claus Niederau, Paul Adams, Wolfgang Stremmel, Louis Griffel, Nicola Lynch, Oliver Schoenborn-Kellenberger, Antonello Pietrangelo

Blood (2009) 114 (22): 1514.

https://doi.org/10.1182/blood.V114.22.1514.1514

Published: 2009

Journal Articles

Comparison of Deferasirox, Deferiprone, and Desferrioxamine Effectiveness on Myocardial Iron Concentrations and Biventricular Function by Quantitative MR in Beta-Thalassemia Major

Blood (2008) 112 (11): 3872.

https://doi.org/10.1182/blood.V112.11.3872.3872

Published: 2008

Journal Articles

Haptoglobin modifies the hemochromatosis phenotype in mice

Emanuela Tolosano, Sharmila Fagoonee, Cinzia Garuti, Linda Valli, Nancy C. Andrews, Fiorella Altruda, Antonello Pietrangelo

Blood (2005) 105 (8): 3353–3355.

https://doi.org/10.1182/blood-2004-07-2814

Published: 2005

Journal Articles

Wild-type HFE protein normalizes transferrin iron accumulation in macrophages from subjects with hereditary hemochromatosis

Giuliana Montosi, Paola Paglia, Cinzia Garuti, Carlos A. Guzman, Judy M. Bastin, Mario P. Colombo, Antonello Pietrangelo

Blood (2000) 96 (3): 1125–1129.

https://doi.org/10.1182/blood.V96.3.1125

Published: 2000

Journal Articles

Inappropriately High Iron Regulatory Protein Activity in Monocytes of Patients With Genetic Hemochromatosis

Gaetano Cairo, Stefania Recalcati, Giuliana Montosi, Elisa Castrusini, Dario Conte, Antonello Pietrangelo

Blood (1997) 89 (7): 2546–2553.

https://doi.org/10.1182/blood.V89.7.2546

Published: 1997

NARROW

Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with β-thalassemia

Luspatercept Increases Hemoglobin, Decreases Transfusion Burden and Improves Iron Overload in Adults with Beta-Thalassemia

Luspatercept (ACE-536) Reduces Disease Burden, Including Anemia, Iron Overload, and Leg Ulcers, in Adults with Beta-Thalassemia: Results from a Phase 2 Study

Randomized, Open Label, Phase IIa Controlled Trials Evaluating the Safety of the Association of Deferasirox with Standard Antiviral Therapy (Peg-interferon and Ribavirin) in Patients with Chronic Hepatitis C

Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel

A Phase I/II, Open-Label, Dose-Escalation Trial of Once-Daily Oral Chelator Deferasirox to Treat Iron Overload in HFE-Related Hereditary Hemochromatosis: Final Results of the Core Study.

Comparison of Deferasirox, Deferiprone, and Desferrioxamine Effectiveness on Myocardial Iron Concentrations and Biventricular Function by Quantitative MR in Beta-Thalassemia Major

Haptoglobin modifies the hemochromatosis phenotype in mice

Wild-type HFE protein normalizes transferrin iron accumulation in macrophages from subjects with hereditary hemochromatosis

Inappropriately High Iron Regulatory Protein Activity in Monocytes of Patients With Genetic Hemochromatosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only